Arterial Embolization Of Persistent Geniculate Arteries For Chronic Pain Management After Total Knee-Replacement Arthroplasty(Knee Embolisation)
Unknown statusNot applicableNCT04417686
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Recent works in interventional radiology have shown interesting results in the treatment of musculoskeletal inflammatory sites by arterial embolization. Supra-selective arterial embolization has been successfully developed by Dr. Okuno (Japan) to manage moderate to severe knee osteoarthritis. Also, inflammation of the surgical site mediated via geniculate arteries is a major cause for persistent chronic post-operative gonalgia.
Study details
- Official title
- Arterial Embolization Of Persistent Geniculate Arteries For Chronic Pain Management After Total Knee-Replacement Arthroplasty: A Feasibility Study (Knee Embolisation)
- Conditions
- Musculoskeletal Inflammatory
- Interventions
- Procedure: arterial embolization
- Sponsor
- Assistance Publique Hopitaux De Marseille
- Start date
- 2021-06-22
- Primary completion
- 2023-08
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- France
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Adult patient (male or female) aged 18-85 * Suffering from moderate to severe chronic pain (EVA \> 50mm) more than 6 months after total prosthetic knee replacement surgery for severe gonarthrosis with impact on quality of life. * And having followed for at least 3 months a well-conducted conservative medical treatment (anti-inflammatory, analgesic, masso-kinesiotherapy). * The patient may initially have had a single or bilateral replacement. The period of 6 months must be respected for each side, between the intervention and the inclusion for homolateral pain. * Patient willing to participate in the study and with signed informed consent. * Patient willing to undergo post-operative monitoring for one year. Exclusion Criteria: Orthopaedic or rheumatological pathologies: * Rheumatoid arthritis * Psoriatic rheumatism * Spondylarthropathies * History of primary or secondary bone tumor, in remission or active. * Myeloma * Operational criteria: * Infection of the surgical site * Re-operation * Severe bleeding * Use of turnstile per-operative * Wound of popliteal artery * Diabetic patient * Comorbidities: * General condition responsible for objective hemostasis disorder (hemophilia, Willebrand disease, thrombocytopenia) and anticoagulant treatments. * Pads 100 G/L
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04417686